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Abstract
Background: Surgical treatment of complicated aortic valve endocarditis often is challenging, even for experienced
surgeons. We aim at demonstrating a standardized surgical approach by stentless bioprostheses for the treatment
of aortic valve endocarditis complicated by paravalvular abscess formation.
Methods: Sixteen patients presenting with aortic valve endocarditis (4 native and 12 prosthetic valves) and
paravalvular abscess formation at various localizations and to different extents were treated by a standardized
approach using stentless bioprostheses. The procedure consisted of thorough debridement, root replacement with
reimplantation of the coronary arteries and correction of accompanying pathologies (aortoventricular and
aortomitral dehiscence, septum derangements, Gerbode defect, total atrioventricular conduction block, mitral and
tricuspid valve involvement).
Results: All highly complex patients included (14 males and 2 females; median age 63 years [range 31–77]) could
be successfully treated with stentless bioprostheses as aortic root replacement. Radical surgical debridement of
infected tissue with anatomical recontruction was feasible. Although predicted operative mortality was high
(median logarithmic EuroSCORE I of 40.7 [range 12.8–68.3]), in-hospital and 30-day mortality rates were favorable
(18.8 and 12.5% respectively).
Conclusions: Repair of active aortic valve endocarditis complicated by paravalvular abscess formation and
destruction of the left ventricular outflow tract with stentless bioprosthesis is a valuable option for both native and
prosthetic valves. It presents a standardized approach with a high success rate for complete debridement, is readily
available, and yields comparable clinical outcomes to the historical gold standard, repair by homografts.
Additionally, use of one type of prosthesis reduces logistical issues and purchasing costs.
Keywords: Infective endocarditis, Stentless bioprostheses, Abscess, High-risk, Surgery
Background
Infective endocarditis causes in-hospital mortality of
20% and 40% after 1-year, rising further to 79% for aortic
valve endocarditis [1, 2]. This high rate is largely due to
extended local destruction of heart tissue, e.g. paravalvu-
lar abscess formation, with secondary heart failure. Risk
factors for endocarditis include rheumatic, congenital,
and degenerative valve lesions, intracardiac prosthetic
material, intravenous drug use, and healthcare contact
[3]. Diagnosis of endocarditis is based on the modified
Duke criteria, bearing a sensitivity and specificity of 80%
for the total patient population [4]. As this is not opti-
mal, the expert opinion of a multidisciplinairy team is
essential for diagnosis. Therapy of endocarditis relies on
antimicrobial therapy and surgery for cardiac anatomical
damage (vegetation, abscess, fistula, shrunken valve,
valve tears or holes, prosthetic valve detachment), as
well as uncontrolled infection. In this way, 25–50% of
patients are operated upon in the acute phase of infec-
tion and an additional 20–40% later in the course due to
haemodynamic complications [5].
Paravalvular abscess formation complicates aortic
valve endocarditis. Early surgical treatment of compli-
cated endocarditis improves outcome when compared to
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medical therapy alone, reducing 6-month mortality from
33 to 16% [6] and the composite endpoint of death/ em-
bolic events/ recurrence of endocarditis from 28 to 3%
[7]. Aortic valve paravalvular abscess formation and root
destruction requires radical resection of infected tissue
with subsequent reconstruction of the left ventricular
outflow tract (LVOT) (modified Bentall procedure) [8].
Therefore, surgical treatment of complicated aortic valve
endocarditis is considered challenging, bearing high op-
erative (11–40% in-hospital) and late (60% in 5 years)
mortality rates [9].
Various surgical techniques are used to treat compli-
cated aortic valve endocarditis, depending on the surgi-
cal preference and with differing results: patch,
prosthesis, homograft. Historically, cryopreserved homo-
grafts were considered as the gold standard for these pa-
tients [10–12]. Homografts offer low recurrence rates,
acceptable valve-related morbidity and mortality, and
their low transvalvular gradient is associated with im-
proved left ventricular mass regression [13, 14]. Homo-
grafts also have disadvantages, including demanding
surgical techniques, the need for reoperation due to cal-
cification, limited availability and shelf life [8, 9, 15].
Nowadays, biological stentless valves are more often
used in complicated aortic valve endocarditis [8, 9].
Using these prostheses, the surgical versatility of homo-
grafts is reached due to their comparable durability,
shape and pliability [8]. In addition, stentless bioprosth-
eses have advantages, such as a rather long shelf life and
being readily available in various sizes, uniform in qual-
ity, technically easier to implant and furnished with
anticalcification properties [8, 13, 14, 16–18].
Guidelines support the use of both homografts and
stentless bioprostheses in aortic valve endocarditis with
paravalvular abscess formation [2, 10, 19]. The choice of
prosthesis depends on patient characteristics, technical
considerations, and surgeon preferences [8, 14]. In this il-
lustrated series of sixteen patients with aortic valve endo-
carditis and complicating paravalvular abscess formation,
we show that the use of stentless bioprostheses provides a
more standardized surgical procedure that consists of
thorough debridement, root replacement with reimplanta-
tion of the coronary arteries, and treatment of accom-
panying pathologies.
Methods
Patients
In this case series we aimed at providing evidence for the
standardized use of a stentless bioprostheses in complex
aortic valve endocarditis. “Standardized use” refers to the
use of one type of stentless bioprosthesis for a variety of
anatomical problems complicating aortic valve endocardi-
tis. Clinical data and high quality macroscopic pictures
from sixteen patients with active aortic valve endocarditis
and paravalvular abscess formation were collected be-
tween 2006 and 2015. In this time period, a total of 85 pa-
tients underwent aortic valve surgery for endocarditis in
our center. Here, we report on those patients treated with
stentless bioprostheses. Their endocarditis was not limited
to the cusps but also involved the annulus with formation
of large paravalvular abscesses at various anatomical loca-
tions. Consequently, complications arose, such as root dis-
arrangement with loss of aortaventricular or aortomitral
continuity, atrioventricular conduction disturbance, or in-
fection of the septum or the right ventricle. Despite their
poor clinical condition, these patients were deemed eligi-
bile for surgical valve repair and LVOT reconstruction
using stentless bioprostheses.
Definitions
Infective endocarditis was diagnosed based on the modified
Duke criteria [4] and expert opinion of a multidisciplinairy
team. Prosthetic valve endocarditis was considered early if
it occurred during the first year after valve replacement,
otherwise it was considered late [2]. Causative micro-
organisms were identified by culture and molecular testing
on peripheral blood and tissue or prosthetic material col-
lected during surgery [2]. Functional cardiac derangements
as described by the guidelines were important indications
for surgery [2, 19]. Macroscopically visible pathological
findings considered an indication for the use of stentless
bioprostheses were presence of destructive lesions, includ-
ing annular abscess, paravalvular leak and cusp perforation.
Re-thoracotomy was defined as reopening of the sternum
after implantation of the bioprosthesis. Reoperation was de-
fined as any surgical procedure involving the implanted
bioprosthesis. Recurrence was used as a combined term for
both relapse (repeat episodes of endocarditis caused by the
same microorganism) and reinfection (infection caused by
a different microorganism) [2].
Fig. 1 Stentless bioprosthesis
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Prosthesis
The Freestyle® bioprosthesis (Medtronic Inc., Minne-
apolis, MN, USA) is a stentless porcine aortic root
prosthesis with ligated coronary arteries and a thin
skirt over the porcine septal myocardium. The bio-
prosthesis is fixed with low pressure applied to the
aortic wall, and zero-net pressure across the leaflets
(Fig. 1). Pre-implantation, the bioprosthesis underwent
an anticalcification treatment using alpha-amino-oleic
acid. The device can be implanted by various techniques:
subcoronary valve replacement, root inclusion, or
complete aortic root replacement.
Surgical technique
The standard surgical approach was a median (re)ster-
notomy with mild/moderate hypothermic (32–34 °C)
cardiopulmonary bypass and cardioplegic cardiac arrest
(retrograde blood cardioplegia). Cardiopulmonary bypass
was performed using aortic cannulation and right atrial
or bicaval cannulation for venous drainage.
The aorta was transected above the sinotubular junction.
After the aortotomy exposure, the abscess regions were
inspected (Fig. 2) and infected native cusps or prosthesis as
well as any aortic aneurysms were removed with extensive
tissue debridement. The aortic sinuses were resected with
Fig. 2 Aortic valve endocarditis with paravalvular abscess formation, surgical view: a view from aortic root, ventricular septal defect, b valved conduit with
vegetations, c total aorto-ventricular dehiscence, with left ventricular outflow tract discontinuity, d abscess cavity (large arrow) with left main coronary visible
(small arrow), e retro-aortal abscess cavity with aorto-mitral involvement and mitral annulus dehiscence, f aorto-atrial fistula, Gerbode-like defect, g atrial
view, tricuspid valve annular abscess with torn septal leaflet and paravalvular leak, h tricuspid valve deformity with vegetational mass
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trumpet-shaped recesses of the coronary ostia. More specif-
ically, a ventricular septum defect just under the membran-
ous septum was identified in Fig. 2a. In this case a
pericardial patch was used, which was distally sutured on
the septum covering both the defect and the membranous
septum, proximally attached at the level of the aortic annu-
lus. Figure 2b and c depict chronic dehiscence of a mechan-
ical prosthesis (implanted after a Bentall procedure) as a
result of abcess formation at the annular level. Inter-
estingly, the prosthesis was found floating above the
annulus, only attached by the coronary arteries.
Hence, the adhesions surrounding the annulus kept
the prosthesis in place. Following resection of the in-
fected prosthesis and clearance of the abcess, the
stentless bioprosthesis was sutured on the annulus
using a single-stitch technique. Given the chronic na-
ture of disease in this case, the bioprosthesis was
parachutted downwards towars the subannular plane
to minimize traction of the chronically anchored an-
terior mitral leaflet (AML). In contrast, Fig. 2d and e
illustrate acute subannular abcess formation. In this
case, the AML was detached from the annulus while
the prosthesis attachment site remained intact. In this
case, due to the recent onset of infection, traction of
the AML to the annulus plane and a neo-annulus
were created after clearance of the abcess and other
inflammatory tissue. Afterwards the stentless bio-
prosthesis was sutured to the annulus. Figure 2f to h
depict Gerbode lesions with tricuspid valve involve-
ment. Gerbode(−like) lesions encompass fistulas
formed between the left ventricle(aorta) and the right
side of the heart, appearing above or below the septal
leaflet of the tricuspid valve. Repair of the sub-
valvular fistula from the right side included temporary
resection of the spetal leaflet of the tricupid valve,
which was thereafter re-attached.
After debridement, restoration and sizing of the aortic
annulus the proximal anastomosis was performed using
20–25 interrupted sutures of Ticron 3–0 in a single
plane. If required, the coronary ostia were mobilised
using diathermy. After completion of the proximal su-
ture line, the patient’s coronary ostia were reimplanted
end-to-side to the corresponding sinus of Valsalva of the
prosthesis using a continuous 5–0 polyproylene suture.
Finally, the bioprosthesis was anastomosed with the
aorta using continuous 4–0 polyproylene. If further re-
section of the ascending aorta was required, a vascular
tube graft was interposed.
Ethical considerations
The institutional medical ethical review board of the
University Medical Center Groningen approved the use
of retrospective patient data for our study and waived in-
formed consent (METc2015/033; February 2015).
Results
Patient characteristics
This series consecutively included 14 males and 2 fe-
males with a median age of 63 years (Tables 1 and 2).
All patients had an urgent indication for cardiothoracic
surgery with implantation of a stentless bioprosthesis as
root replacement due to uncontrolled infection and ab-
scess formation (evidence class I and level B [2]). Me-
dian New York Heart Association score was III, and
median logarithmic EuroSCORE I score was 40.7. Me-
dian follow-up for survivors was 4.6 years. All survivors
were followed for at least 2 years, 36% were followed for
5 years, and 9% for 10 or more years. In 4 patients (25%)
the endocarditis involved native aortic valves, with 2
identified bicuspid valves. In 12 patients (58%) the endo-
carditis involved prosthetic aortic valves: in 7 patients
the aortic valve was replaced once and in 1 patient twice
before, in 5 patients a Bentall procedure had been
Table 1 Patient characteristics (n = 16
Characteristic Value
Age: median [range] (years) 63 [31–77]
Gender: male; female, n (%) 14 (87.5); 2 (12.5)
Reoperation / PVE (%) 75
Follow-up survivors: median [range] (years) 4.6 [2.3–11.7]
NYHA score: median [range] III [II-IV]
Logarithmic EuroSCORE I: median [range] 40.7 [12.8–68.3]
Microbiology
PVE
• Staphylococcus spp.: 5 CoNS,
1 S. aureus
n = 6 (50%)
• Streptococcus spp.: 1 viridans group,
1 S. bovis, 1 S. agalactiae
n = 3 (25%)
• Enterococcus spp.: 2 E. faecalis n = 2 (17%)
• no micro-organism identified n = 1 (8%)
NVE
• Staphylococcus spp.: S. aureus n = 1 (25%)
• Streptococcus spp.: 2 viridans group n = 2 (50%)
• Enterococcus spp.: E. faecalis n = 1 (25%)
Outcome Value
Cardiopulmonary bypass perfusion time:
median [range] (minutes)
358 [186–731]
Aortic cross-clamping time: median [range]
(minutes)
266 [107–389]
Intensive care unit stay: median [range] (days) 1.5 [1–21]
Hospital stay: median [range] (days) 55 [29–90]
In-hospital mortality: n (%) 3 (18.8)
30 day mortality: n (%) 2 (12.5)
CoNS coagulase negative staphylococci, COPD chronic obstructive pulmonary
disease, e.c.i. e cause ignota, NVE native valve endocarditis, NYHA New York
Heart Association, PVE prosthetic valve endocarditis, SD standard deviation
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Table 2 Characteristics of included patients
# Age
(yr)
sex Previous
surgery
Micro-organism Indication for surgery Euro
SCORE
Remarks during
stentless bioprosthesis
implantation
Outcome
rethoracotomy re-IE permanent
dialysis
PPM
1 66 M 2 yr. bio Streptococcus
sanguinis
aortic root abscess 38.92 pericard patch to
support MV, 1 RBC
Recovery initially, but death
7.5 months post surgery
– + – +
2 70 M 1 yr. bio Staphylococcus
epidermidis
aortic root abscess,
mycotic aneurysm,
loose prosthesis,
septic emboli, AV
block
65.87 aorta annulus support
with pledges and
transseptal stiches,
CABG, 5 RBC
In-hospital death 40 days
post surgery
– – – +
3 71 M 1 yr. bio Streptococcus
agalactiae
aortic root abscess
with Gerbode defect,
AV block
47.06 pericard patch
reconstruction aorta
annulus, atriotomy,
TVP and Devega
plasty, 14 RBC
Recovery > 6 years post
surgery
– – – +
4 31 M – Streptococcus mitis totally destructed
LVOT with Gerbode
defect, AV block
42.52 pericard patch
reconstruction aorta
annulus, TVP, Devega
plasty, 0 RBC
Recovery > 4 years post
surgery
– – – +
5 71 M 29 yr. mech Enterococcus
faecalis
aortic root abscess,
septic emboli
47.06 3 RBC Recovery > 3 years post
surgery
– – – –
6 36 M 2 yr. mech not identified aortic root abscess,
septic emboli
28.55 0 RBC Recovery > 4 years post
surgery
– – – –
7 64 M – Staphylococcus
aureus
aortic root abscess,
multiple septic
emboli, cardiac
decompensation
23.42 aorta annulus support
with pledges, 2 RBC
Recovery > 2 year
(20 months) post surgery
– – – +
8 72 M 3mo bio Staphylococcus
epidermidis
loose prosthesis,
cardiac
decompensation
64.48 closure of destructed
coronary ostia, CABG,
0 RBC
In-hospital death 14 days
post surgery
– – – –
9 45 M 12 yr. mech Staphylococcus
aureus
aortic root abscess,
mycotic aneurysm
28.55 multiple vegetations
AV, pericard patch
reconstruction aorta
annulus, 0 RBC
Recovery initially, but death
13 months post surgery
– + – +
10 60 F 4mo bio Staphylcoccus
epidermidis
progressive aortic root
abscess with Gerbode
defect, septic emboli,
blood cultures
persistantly positive,
AV-block
37.28 removal of vegetation
from right atrium with
affected AML and
PPM implantation, 4
RBC
Recovery > 2 years post
surgery
– – – +
11 55 M – Enterococcus
faecalis
aortic root abscess,
mycotic aneurysm,
conduction
disturbance
26.62 pericard patch
reconstruction aorta
annulus and AML, 1
RBC
Recovery > 4 years post
surgery
– – – –
12 42 M – Streptococcus
mutans
mycotic aneurysm,
large vegetation
12.79 MVP, 0 RBC Recovery > 5 years post
surgery
– – – –
13 75 F 1 yr. bio Staphylococcus
epidermidis
aortic wall thickening,
septic emboli, AV
block
61.76 mobilization of tightly
adhered coronary
ostia, 2 RBC
Recovery > 8 years post
surgery
– – – +
14 77 M 2 yr. bio Enterococcus
faecalis
septal mycotic
aneurysm with fistula
and threatened
anatomy
52.33 urgent surgery with
two times
reanimation setting
and persistant
instability for which
In-hospital death directly
post surgery
– – – –
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Table 2 Characteristics of included patients (Continued)
# Age
(yr)
sex Previous
surgery
Micro-organism Indication for surgery Euro
SCORE
Remarks during
stentless bioprosthesis
implantation
Outcome
rethoracotomy re-IE permanent
dialysis
PPM
sternum left open, 0
RBC
15 62 M 1 yr. mech coagulase
negative
Staphylococci
aortic root abscess,
progressive mycotic
aneurysm,
aortoventricular
dehiscence
68.31 4 RBC Recovery > 11 years post
surgery
– – – –
16 60 M 7 yr. mech Streptococcus
bovis
aortic root abscess,
mycotic aneurysm,
aortoventricular
dehiscence, cardiac
decompensation
60.7 drainage of 1 L
pleural effusion at
both sides,
0 RBC
Recovery > 5 years
post surgery
– – – –
# patient number, AML anterior mitral leaflet, AV aortic valve, AV block atrio-ventricular block, bio biological prosthetic valve inplanted, CABG coronary artery bypass
grafting, EuroSCORE logarithimic I, F female, LVOT left ventricular outflow tract, M male, mech mechanical prosthetic valve inplanted, mo months, MV mitral valve,
PPM placement of permanent pacemaker, RBC number of bags with red blood cells given during surgery, re-IE recurrence of endocarditis, rethoracotomy for bleeding or
tamponade, TVP tricuspid valve plasty, yr. years
Fig. 3 Aortic valve endocarditis with paravalvular abscess formation, transesophageal echocardiographic view
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performed. Of the patients with prosthetic valves, 2 pa-
tients had early (3–4 months after surgery) and 10 pa-
tients late endocarditis (1–29 years after surgery). In-
hospital and 30 day mortality were 18.8% and 12.5%, re-
spectively; 2-year recurrence rate was 14%.
Infectious cardiac anatomical compliations eligible for
stentless bioprostheses repair
Several situations of active aortic valve endocarditis with
paravalvular abscess formation and accompanying patholo-
gies were deemed eligible for valve repair and LVOT recon-
struction with a stentless bioprosthesis (Figs. 2, 3, 4 and 5).
Aortoventricular dehiscence
Seven patients with a prosthetic valve presented with
aortoventricular dehiscence. Pathogens included
coagulase-negative staphylococci, Staphylococcus aureus,
Streptococcus bovis, Enterococcus faecalis. 29% (2/7) of
these patients also had extention of infection towards
their mitral valve.
Septum derangements
Seven patients presented with infectious derangements
of their septum, including vegetations and perforations.
Four of these patients had a prosthetic valve. Pathogens
included Staphylococcus epidermidis, Staphylococcus
aureus, Streptococcus agalactiae, Streptococcus mitis,
and Enterococcus faecalis. 71% (5/7) of these patients
had a permanent pacemaker (PPM) implanted and 43%
(3/7) had extention of infection towards the right side of
the heart through a Gerbode(−like) defect.
Total atrioventricular conduction block
Six patients presented with a total or third degree atrio-
ventricular conduction block. Five of these patients had a
prosthetic valve. Pathogens included Staphylococcus epi-
dermidis, Streptococcus sanguinis, Streptococcus agalac-
tiae, and Streptococcus mitis. All these patients had a PPM
implanted, 50% had extention of infection towards their
right ventricle through a Gerbode(−like) defect, and 50%
had extention of infection towards their mitral valve.
Gerbode defect (with tricuspid valve involvement)
Three patients presented with a Gerbode(−like) defect, a
left ventricular (aorta) to right atrial shunt [20], causing
an infection of their tricuspid valve due to local spread.
Two of these patients had a prosthetic valve. Pathogens
included Staphylococcus epidermidis, Streptococcus aga-
lactiae and Streptococcus mitis. All patients had a PPM
implanted, and needed a tricuspid valve plasty.
Mitral valve involvement (with aortomitral dehiscence)
Seven patients presented with extension of infection
towards their mitral valve. Five of these patients had a
prosthetic valve. Pathogens included Staphylococcus epi-
dermidis, Streptococcus sanguinis, Streptococcus mutans,
and Enterococcus faecalis. 57% (4/7) of these patients
had septic emboli.
Fig. 4 Aortic valve endocarditis with paravalvular abscess formation, nuclear/radiological view with 18F-fluorodeoxyglucose positron emission
tomography/computed tomography
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Extracardiac complications due to endocarditis
Infective endocarditis is a cardiac disease with extracardiac
complications due to hematogenous and embolic spread.
In our series, the three most common complications were:
mycotic aneurysm (n = 3), cerebral emboli (n = 2), and ver-
tebral osteomyelitis (n = 2).
Patient survival
Figure 6 shows the survival of included patients for
11 years. Five patients died during this period (Table 2),
due to: end-stage heart failure 227 days post-surgery; re-
current respiratory insufficiency resulting from sputum
retention, encephalopathy and extended postoperative
wound infection 40 days post-surgery; active intra-
cerebral bleeding without therapeutic options 14 days
post-surgery; re-infection of the prosthesis with cerebral
embolization, mediastinitis and kidney failure 388 days
post-surgery; severe hemodynamic instability immedi-
ately post-surgery.
Discussion
We have described and illustrated a series of patients with
aortic valve endocarditis, paravalvular abscess formation
and accompanying pathologies. All patients underwent car-
diothoracic surgery with thorough debridement and restor-
ation of cardiac anatomy using stentless bioprostheses.
Patients with native and several types of prosthetic valves
were included. Pathogens varied, including staphylococci
(n = 7), streptococci (n = 5) and enterococci (n = 3). Pre-
dicted mortality was high (median logarithmic EuroSCORE
I of 40.7 [range 12.8–68.3]) but actual mortality was rela-
tively low (in-hospital 18.8% [3/16] and 30-day 12.5% [2/
16]), showing that the stentless bioprostheses can be suc-
cessfully used in a variety of surgically challenging situations
and allows for a standardized approach. Figures 2, 3 and 4
show the cases of aortic valve endocarditis with various
paravalvular abscesses from a surgical (Fig. 2), echocardio-
graphic (Fig. 3) and nuclear/radiological (Fig. 4) view.
Due to its design, it is possible to use the stentless bio-
prostheses for subcoronary valve replacement, for inclu-
sion of the root, or full root replacement [13, 16]. Using
the prostheses for a full root replacement, enables exclu-
sion of abscess cavities and the rebuilding of the LVOT.
Furthermore, it maintains root geometry and the integrity
of the “leaflet, sinus and root” as a functional entity, both
Fig. 5 Aortic valve endocarditis with paravalvular abscess formation,
illustrations: a coronal view on the heart showing a ventricular septum
defect, Gerbode defect (communication between the left ventricle and
the right atrium), Gerbode-like defect (communication between the
aorta and the right atrium) and tricuspid valve deformity; b coronal
view on the proximal heart showing total aorto-ventricular dehiscence;
c horizontal view on the proximal heart showing a retro-aortal abscess
cavity with aorto-mitral involvement and mitral annulus dehiscence
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increasing durability of the bioprostheses [8, 21]. Implant-
ation with the single suture technique is believed to allow
placement of the stentless bioprosthesis as full root re-
placement without narrowing of the LVOT nor obstruc-
tion by any rigid structures such as pledgets [21]. Using
the stentless bioprothesis as a full root replacement in
complex endocarditis was previously reported in 5 pa-
tients [22] and now supported with our data of 16 patients
with various well described paravalvular abscesses.
Survival rates for the use of stentless bioprostheses when
active native or prosthetic aortic valve endocarditis is com-
plicated by extensive destruction of the LVOT have been
reported as 81–89%, 76–83%, 62–70%, and 54% at 30 days,
1 year, 5 years, and 10 years, respectively [8, 13, 14, 16, 17].
Although early mortality remains considerably high in the
group presented, studies show that stentless bioprostheses
yield clinical outcomes, postoperative echocardiographic
data, long-term recurrence and survival rates comparable
to those of cryopreserved homografts [8, 9, 13, 14, 16, 17].
Indeed, the recurrence rates of homografts (3.8–6.8%) and
stentless valves (3.7–8.6%) are similar and lower than that
of standard prostheses (33%) [13]. However, as compared
with standard aortic valve replacement, the need for re-
implantation of coronary arteries conveys an increased risk
of atrioventricular conduction block. Also, the use of bio-
prosthesis conveys an increased risk of reoperation in ju-
venile patients. Even though stentless and stented valves
show equal performance with regard to clinical parameters
and valve-related mortality, stentless valves have more fa-
vorable hemodynamic and biomechanical characteristics
and significantly higher long-term survival rates (78% ver-
sus 66% in 8-years) [8, 14, 16]. Compared to homografts,
progression of valve dysfunction (37% versus 86%, p < 0.01)
[23] and need for reoperations are lower for stentless bio-
prostheses [14, 18, 23]. Furthermore, implantation is less
challenging and demanding for stentless bioprostheses and
reoperation of a calcified prosthesis may be easier as com-
pared to homografts [9].
A limitation of this study is its retrospective nature.
Furthermore, we did not directly compare the Freestyle®
bioprosthesis with other stentless bioprostheses, nor
with homografts. The described patient group had been
previously treated with homografts, but we did not con-
sider it useful to compare results from 10 years ago with
recent results. Prospective studies should examine dur-
ability and long-term valve-related complication free
survival of patients treated with various models of stent-
less bioprostheses. Experience with reoperation for re-
placing a bioroot also needs further examination [21].
Conclusion
Aortic valve endocarditis with paravalvular abscess for-
mation remains a therapeutic challenge for which stent-
less bioprosthesis is a credible surgical option. This
prosthesis allows a radical and uniform approach with a
good surgical overview and use of limited prosthetic ma-
terial. It enables successful treatment of complex aortic
valve endocarditis with complete debridement, elimin-
ation of shunts and anatomical deviations, reconstruc-
tion of the LVOT and aortomitral continuity. Stentless
bioprostheses yield comparable clinical outcomes as the
historical gold standard – the homograft – and are read-
ily available. Of note, use of one type of prosthesis re-
duces logistical issues and purchasing costs.
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